ClinicalTrials.gg

Program

repotrectinib

Also written as “Repotrectinib”, “Oral repotrectinib (TPX-0005)” and “TPX-0005”.

Its studies are mostly in Neoplasm Metastasis · Lymphoma · Carcinoma, Non-Small-Cell Lung · Sarcoma · Lymphoma, Follicular, led by Bristol-Myers Squibb.

Furthest: phase 3, since Nov 15, 20239 company-led studies, 3 open or runningNext primary completion: Feb 16, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb93 open or runningphase 3since Nov 15, 2023Mar 6, 2017Feb 16, 2027phase 3 · NCT06140836

Also a collaborator on its studies: Zai Lab.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2017First study: phase 2 study in SarcomaFirst studyNCT03093116 · 500 planned · United States, Australia, Belgium and more
  2. Sep 12, 2019Phase 2 study in LymphomaNCT04094610 · 75 planned · United States, Australia, Canada and more
  3. Sep 13, 2021Phase 2 study in Neoplasm MetastasisNCT05071183 · 9 enrolled · United States
  4. Mar 28, 20232 phase 1 studies in Neoplasm MetastasisNCT05828303, NCT05828277
  5. Nov 15, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06140836 · 190 enrolled · United States, Argentina, Austria and more
  6. Apr 3, 2024Phase 1 study in Lymphoma, FollicularNCT06352528 · 18 enrolled · United States
  7. Jun 25, 2024Phase 1 study in Healthy VolunteersNCT06493409 · 32 enrolled · United States
  8. Oct 30, 2025Phase 1 study in Healthy VolunteersNCT07223671 · 30 enrolled · United States

Ahead

  1. Feb 16, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06140836
  2. Feb 29, 2028Primary completion: phase 2 study in SarcomaNCT03093116

TargetBeta

“An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), ”NCIt, by rule
“Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; NT-3 growth factor receptor inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07223671Healthy Volunteers · United States1CompletedFeb 19, 202630
NCT06493409Healthy Volunteers · United States1CompletedDec 7, 202432
NCT06352528Lymphoma, Follicular · United States1CompletedSep 16, 202518
NCT06140836Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3Active, not recruitingFeb 16, 2027190
NCT05828303Neoplasm Metastasis · United States, Australia, Brazil and more1WithdrawnJul 31, 20250
NCT05828277Neoplasm Metastasis · United States, Spain1WithdrawnAug 31, 20250
NCT05071183Neoplasm Metastasis · United States2TerminatedMar 1, 20239
NCT04094610Lymphoma · United States, Australia, Canada and more2RecruitingSep 30, 202675
NCT03093116Sarcoma · United States, Australia, Belgium and more2RecruitingFeb 29, 2028500

How it is read

Names in the registry

  • “Repotrectinib”, 4 entries
  • “Oral repotrectinib (TPX-0005)”, 2 entries
  • “TPX-0005”, 2 entries
  • “repotrectinib (TPX-0005)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.